Showing results (121-130 of 245) with videos related to

Sort By:
Pageof 25
Cancer|April 2, 2011
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaMeir Wetzler, Chris Andrews, Laurie A Ford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.
Annals of Hematology|September 22, 2011
Is obesity a prognostic factor for acute myeloid leukemia outcome?Hun Ju Lee, Andrea S Licht, Andrew J Hyland, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimensSarah M Kashanian, Noa G Holtzman, Ciera L Patzke, et al.
Frontiers in Oncology|April 18, 2022
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort StudyMoaath K Mustafa Ali, Elizabeth M Corley, Hanan Alharthy, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2019
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimationSunil Adige, Rena G Lapidus, Brandon A Carter-Cooper, et al.
Cancer|December 4, 2014
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center studyVishal Bhatnagar, Yin Wu, Olga G Goloubeva, et al.
Journal of Clinical Microbiology|April 9, 2004
Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipientImad Dibo, Satish K Pillai, Howard S Gold, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 7, 2019
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II StudyBrittany Knick Ragon, Olatoyosi Odenike, Maria R Baer, et al.
Acta Haematologica|January 30, 2019
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and PonatinibFiras El Chaer, Noa G Holtzman, Edward A Sausville, et al.
Pageof 25